Rifampicin does not prevent amyloid fibril formation by human islet amyloid polypeptide but does inhibit fibril thioflavin-T interactions: Implications for mechanistic studies of β-cell death

Biochemistry

Volumn 47, Issue 22, 2008, Pages 6016-6024

  Meng, Fanling ^a   Marek, Peter ^a   Potter, Kathryn J ^b   Verchere, C Bruce ^b   Raleigh, Daniel P ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DATA REDUCTION; DISEASES; MEDICAL PROBLEMS; OXIDATION; TOXICITY;

AMYLOID FIBRILS; AMYLOID FORMATION;

POLYPEPTIDES;

AMYLIN; AMYLOID; PROTEIN DERIVATIVE; RIFAMPICIN; THIOFLAVINE;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG MECHANISM; DRUG SCREENING; DRUG STABILITY; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; RAT;

AMYLOID; ANTIOXIDANTS; CELL DEATH; HUMANS; ISLETS OF LANGERHANS; MICROSCOPY, ELECTRON, TRANSMISSION; RIFAMPIN; THIAZOLES;

EID: 44449160026     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi702518m     Document Type: Article

References (51)

1. Chiti, F., and Dobson, C. M. (2006) Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 75, 333-366.
2. Vendruscolo, M. Z. J., MacPhee, C. E., and Dobson, C. M. (2003) Protein folding and misfolding: A paradigm of self-assembly and regulation in complex biological systems. Philos. Trans. R. Soc. London, Ser. A 361, 1205-1222.
3. Kahn, S. E., Andrikopoulos, S., and Verchere, C. B. (1999) Islet amyloid: A long recognized but underappreciated pathological feature of type II diabetes. Diabetes 48, 241-246.
4. Clark, A., Wells, C. A., Buley, I. D., Cruickshank, J. K., Vanhegan, R. I., Matthews, D. R., Cooper, G. J., Holman, R. R., and Turner, R. C. (1988) Islet amyloid, increased β-cells, reduced β-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res. Clin. Pract. 9, 151-159.
5. Westermark, P., Wernstedt, C., Wilander, E., Hayden, D. W., O'Brien, T. D., and Johnson, K. H. (1987) Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc. Natl. Acad. Sci. U.S.A. 84, 3881-3885.
6. Cooper, G. J. S., Willis, A. C., Clark, A., Turner, R. C., Sim, R. B., and Reid, K. B. M. (1987) Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc. Natl. Acad. Sci. U.S.A. 84, 8628-8632.
7. Cooper, G. J. S. (1994) IAPP compared with calcitonin gene-related peptide: structure, biology, and relevance to metabolic disease. Endocr. Rev. 15, 163-201.
8. Kahn, S. E., D'Alessio, D. A., Schwartz, M. W., Fujimoto, W. Y., Ensinck, J. W., Taborsky, G. J., and Porte, D. (1990) Evidence of cosecretion of islet amyloid polypeptide and insulin by beta-cells. Diabetes 39, 634-638.
9. Marzban, L., Trigo-Gonzalez, G., Zhu, X., Rhodes, C. J., Halban, P. A., Steiner, D. F., and Verchere, C. B. (2004) Role of β-cell prohormone convertase PC (1/3) in processing of pro-islet amyloid polypeptide. Diabetes 53, 141-148.
10. Sanke, T., Bell, G. I., Sample, C., Rubenstein, A. H., and Steiner, D. F. (1988) An islet amyloid peptide is derived from an 89-amino acid precursor by proteolytic processing. J. Biol. Chem. 263, 17243-17246.
11. Lorenzo, A., Razzaboni, B., Weir, G. C., and Yankner, B. A. (1994) Pancreatic islet cell toxicity of Amylin associated with type II diabetes mellitus. Nature 368, 756-760.
12. Clark, A., Lewis, C. E., Willis, A. C., Cooper, G. J. S., Morris, J. F., Reid, K. B. M., and Turner, R. C. (1987) Islet amyloid formed from diabetes-associated peptide may be pathogenic in type-2 diabetes. Lancet 2, 231-234.
13. Hull, R. L., Westermark, G. T., Westermark, P., and Kahn, S. E. (2004) Islet amyloid: A critical entity in the pathogenesis of type 2 diabetes. J. Clin. Endocrinol. Metab. 89, 3629-3643.
14. Clark, A., Wells, C. A., Buley, I. D., Cruickshank, J. K., Vanhegan, R. I., Matthews, D. R., Cooper, G. J., Holman, R. R., and Turner, R. C. (1988) Islet amyloid, increased β-cells, reduced β-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res. Clin. Pract. 9, 151-159.
15. Hayden, M. R., Karuparthi, R. R., Manrique, C. M., Lastra, G., Habibi, J., and Sowers, J. R. (2007) Longitudinal ultrastructure study of islet amyloid in the HIP rat model of type 2 diabetes mellitus. Exp. Biol. Med. 232, 772-779.
16. Rochet, J. (2007) Novel therapeutic strategies for the treatment of protein-misfolding diseases. Expert Rev. Mol. Med. 9, 1-31.
17. Cohen, T., Frydman-Marom, A., Rechter, M., and Gazit, E. (2006) Inhibition of amyloid fibril formation and cytotoxicity by hydroxy-indole derivatives. Biochemistry 45, 4727-4735.
18. Porat, Y., Mazor, Y., Efrat, S., and Gazit, E. (2004) Inhibition of islet amyloid polypeptide fibril formation: A possible role for hetroaromatic interactions. Biochemistry 43, 14454-14462.
19. Scrocchi, L. A., Chen, Y., Waschuk, S., Wang, F., Cheung, S., Darabie, A. A., McLaurin, J., and Fraser, P. E. (2002) Design of peptide-based inhibitors of human islet amyloid polypeptide fibrillogenesis. J. Mol. Biol. 318, 697-706.
20. Abedini, A., Meng, F., and Raleigh, D. P. (2007) A single-point mutation converts the highly amyloidogenic human islet amyloid polypeptide into a potent fibrillization inhibitor. J. Am. Chem. Soc. 129, 11300-11301.
21. Yan, L. M., Tatarek-Nossol, M., Velkova, A., Kazantziz, A., and Kapurniotu, A. (2006) Design of a mimic of nonamyloidogenic and bioactive human islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP cytotoxic fibrillogenesis. Proc. Natl. Acad. Sci. U.S.A. 103, 2046-2051.
22. Pepys, M. B. (2001) Pathogenesis, diagnosis and treatment of systemic amyloidosis. Philos. Trans. R. Soc. London, Ser. B 356, 203-210.
23. Lansbury, P. T., and Lashuel, H. A. (2006) A century-old debate on potein aggregation and neurodegeneration enters the clinic. Nature 443, 774-779.
24. Kirkitadze, M. D., Bitan, G., and Teplow, D. B. (2002) Paradigm shifts in Alzheimer's disease and other neuro degenerative disorders: The emerging role of oligomeric assemblies. J. Neurosci. Res. 69, 567-577.
25. Walsh, D. M., and Selkoe, D. J. (2004) Oligomers in the brain: The emerging role of soluble protein aggregates in neurodegeneration. Protein Pept. Lett. 11, 213-228.
26. Caughey, B., Jr. (2003) Protofibrils, pores, fibrils and neurodegeneration: Separating responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 26, 267-298.
27. Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., and Glable, C. G. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489.
28. Janson, J., Ashley, R. H., Harrison, D., McIntyre, S., and Butler, P. C. (1999) The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48, 491-498.
29. Isaacs, A., Senn, D., Yuan, M., Shine, J., and Yankner, B. (2006) Acceleration of amyloid β-peptide aggregation by physiological concentrations of calcium. J. Biol. Chem. 281, 27916-27923.
30. Hori, Y., Hashimoto, T., Wakutani, Y., Urakami, K., Nakashima, K., Condron, M., Tsubuki, S., Saido, T., Teplow, D., and Iwatsubo, T. (2007) The Tottori (D7N) and English (H6R) Familial Alzheimer Disease mutations accelerate Aβ fibril formation without increasing protofibril formation. J. Biol. Chem. 282, 4916-4923.
31. Grudzielanek, S., Velkova, A., Shukla, A., Smirnovas, V., Tatarek-Nossol, M., Rehage, H., Kapurniotu, A., and Winter, R. (2007) Cytotoxicity of Insulin within its self-assembly and amyloidogenic pathways. J. Biol. Chem. 282, 372-384.
32. Meier, J. J., Kayed, R., Lin, C.-Y., Gurlo, T., Haataja, L., Jayasinghe, S., Langen, R., Glabe, C. G., and Butler, P. C. (2006) Inhibition of human IAPP fibril formation does not prevent β-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP. Am. J. Physiol. 291, E1317-E1324.
33. Namba, Y., Kawatsu, K., Izumi, S., Ueki, A., and Ikeda, K. (1992) Neurofibrillary tangles and senile plaques in brain of elderly leprosy patients. Lancet 340, 978.
34. Chui, D. H., Tabira, T., Izumi, S., Koya, G., and Ogata, J. (1994) Decreased beta-amyloid and increased abnormal Tau deposition in the brain of aged patients with leprosy. Am. J. Pathol. 145, 771-775.
35. Tomiyama, T., Asano, S., Suwa, Y., Morita, T., Kataoka, K., Mori, H., and Endo, N. (1994) Rifampicin prevents the aggregation and neurotoxicity of amyloid β protein in vitro. Biochem. Biophys. Res. Commun. 204, 76-83.
36. Matsuzaki, K., Noguch, T., Wakabayashi, M., Ikeda, K., Okada, T., Ohashi, Y., Hoshino, M., and Naiki, H. (2007) Inhibitors of amyloid β-protein aggregation mediated by GM1-containing raft-like membranes. Biochim. Biophys. Acta 1768, 122-130.
37. Tomiyama, T., Shoji, A., Kataoka, K., Suwa, Y., Asano, S., Kaneko, H., and Endo, N. (1996) Inhibition of amyloid β protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger. J. Biol. Chem. 271, 6839-6844.
38. Lieu, V. H., Wu, J. W., Wang, S. S.-S., and Wu, C.-H. (2007) Inhibition of amyloid fibrillization of hen egg-white lysozymes by rifampicin and p-benzoquinone. Biotechnol. Prog. 23, 698-706.
39. Li, J., Zhu, M., Rajamani, S., Uversky, V. N., and Fink, A. L. (2004) Rifampicin inhibits α-synuclein fibrillation and disaggregates fibrils. Chem. Biol. 11, 1513-1521.
40. Xu, J., Wei, C., Xu, C., Bennett, M. C., Zhang, G., Li, F., and Tao, E. (2007) Rifampicin protects PC12 cells against MPP +-induced apoptosis and inhibits the expression of an α-synuclein multimer. Brain Res. 1139, 220-225.
41. Tomiyama, T., Kaneko, H., Kataoka, K., Asano, S., and Endo, N. (1997) Rifampicin inhibits the toxicity of pre-aggregated amyloid peptides by binding to peptide fibrils and preventing amyloid-cell interaction. Biochem. J. 322, 859-865.
42. Haataja, L., Gurlo, T., Huang, C. J., and Butler, P. C. (2007) Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr. Rev. . (doi:10.1210/er.2007-037).
43. Harroun, T. A., Bradshaw, J. P., and Ashley, R. H. (2001) Inhibitors can arrest the membrane activity of human islet amyloid polypeptide independently of amyloid formation. FEBS Lett. 507, 200-204.
44. Abedini, A., and Raleigh, D. P. (2005) Incorporation of pseudoproline derivatives allow the facile synthesis of human IAPP; a highly amyloidogenic and aggregation-prone polypeptide. Org. Lett. 7, 693-696.
45. Abedini, A., Singh, G., and Raleigh, D. P. (2006) Recovery and purification of highly aggregation-prone disulfide-containing peptides: Application to islet amyloid polypeptide. Anal. Biochem. 351, 181-186.
46. Benetton, S. A., Kedor-Hackmann, E. R. M., Santoro, M. I. R. M., and Borges, V. M. (1998) Reversed-phase high performance liquid chromatographic determination of rifampin in the presence of its acid-induced degradation products. J. Liquid Chromatogr. Relat. Technol. 21, 3215-3221.
47. Furesz, S. (1970) Chemical and biological properties of rifampicin. Antibiot. Chemother. 16, 316-351.
48. LeVine, H. (1995) Thioflavin T interactions with amyloid β-sheet structures. Amyloid: Int. J. Exp. Clin. Invest. 2, 1-6.
49. Marek, P., Gupta, R., and Raleigh, D. P. (2007) The fluorescent amino acid 4-cyanophenylalanine provides a non-invasive intrinsic probe of amyloid formation. ChemBioChem . (in press).
50. Tucker, M. J., Oyola, R., and Gai, F. (2006) A novel fluorescent probe for protein binding and folding studies: p-cyano-phenylalanine. Biopolymers 83, 571-576.
51. Aprilakis, K. N., Taskent, H, and Raleigh, D. P. (2007) Use of the novel fluorescent amino acid p-cyano-phenylalanine offers a direct probe of hydrophobic core formation during the folding of the N-terminal domain of the ribosomal protein L9 and provides evidence for two-state folding. Biochemistry 46, 12308-12313.